Investigational drug · Phase 2
single CNCT19
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
11
Any phase or sponsor naming "single CNCT19"
First trial start
2020
Oct 26, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "single CNCT19", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Acute Lymphoblastic Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma
Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "single CNCT19" as an intervention, largest first.
Juventas Cell Therapy Ltd.Industry
NCT04684147 · 100 participants (planned) · Start Dec 24, 2020 · Primary completion Sep 22, 2022
Drug: single dose of CNCT19 · For: Relapsed or Refractory Acute Lymphoblastic Leukemia
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 11 sites in all
Juventas Cell Therapy Ltd.Industry
NCT04586478 · 60 participants (planned) · Start Oct 26, 2020 · Primary completion Mar 30, 2024
Drug: single dose of CNCT19 · For: Non-Hodgkin's Lymphoma
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 17 sites in all
Juventas Cell Therapy Ltd.Industry
NCT05667506 · 47 participants (planned) · Start Feb 7, 2023 · Primary completion May 30, 2025
Drug: single dose of CNCT19 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Hefei, China; Chongqing, China; Guangzhou, China · 9 sites in all
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT04690192 · 30 participants · Start Jan 1, 2021 · Primary completion Dec 30, 2023
Drug: CNCT19; Gemcitabine Injection and 2 more · For: Large B-cell Lymphoma
Sites: Tianjin, China
Juventas Cell Therapy Ltd.Industry
NCT06316791 · 24 participants (planned) · Start Dec 14, 2021 · Primary completion Dec 13, 2025
Drug: single dose of CNCT19 · For: Lupus Erythematosus, Systemic
Sites: Zhengzhou, China
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Not yet recruiting
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT06777264 · 20 participants (planned) · Start Jan 15, 2025 · Primary completion Dec 15, 2026
Drug: Biological: single dose of Inaticabtagene autoleucel · For: Acute Lymphoblastic Leukemia; B Cell ALL
Shandong UniversityAcademic, hospital or other
NCT04011293 · 20 participants (planned) · Start Jul 2019 · Primary completion Jul 2020
Drug: CNCT19 · For: Relapsed or Refractory Hematological Malignancies
Sites: Jinan, China
- Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1Recruiting
Ruijin HospitalAcademic, hospital or other
NCT06718244 · 20 participants (planned) · Start Oct 31, 2024 · Primary completion Dec 31, 2029
Drug: single dose of Inaticabtagene autoleucel · For: Acute Lymphoblastic Leukemia
Sites: Shanghai, China
- A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesRecruiting
Juventas Cell Therapy Ltd.Industry
NCT07275736 · 18 participants (planned) · Start Mar 1, 2025 · Primary completion Jun 1, 2027
Drug: CNCT19 cell injection · For: Neurological Autoimmune Diseases
Sites: Beijing, China
Juventas Cell Therapy Ltd.Industry
NCT04230473 · 10 participants · Start Mar 13, 2020 · Primary completion Dec 1, 2020
Drug: single dose of CNCT19 · For: Relapsed or Refractory Acute Lymphoblastic Leukemia
Sites: Zhengzhou, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.